IMVT
Immunovant Inc
NASDAQ: IMVT · HEALTHCARE · BIOTECHNOLOGY
$39.95
+0.53% today
Updated 2026-08-07
Market cap
$7.93B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.77
Dividend yield
—
52W range
$14 – $41
Volume
1.3M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C7.5
Quality
B+3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
1.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →211 stocks currently score above 75
Price targets
Analyst target
$46.88
+17.35%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy11 Buy5 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z 1.64 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-95.07M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-210.96M | $-259.34M | $-413.84M | $-505.61M | $-147.86M |
| EPS | — | — | — | — | $-2.77 |
| Free cash flow | $-188.39M | $-214.59M | $-376.63M | $-407.32M | $-95.07M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-07-24 | PANDE, ATUL | Sale | 1,500 | — |
| 2026-07-24 | PANDE, ATUL | Sale | 1,500 | $39.80 |
| 2026-07-23 | STOUT, JAY S | Sale | 2,857 | $38.69 |
Peer comparison
Smart narrative
Immunovant Inc trades at $39.95. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.64, it sits in the distress.
Frequently asked questions
What is Immunovant Inc's stock price?
Immunovant Inc (IMVT) trades at $39.95.
Is Immunovant Inc overvalued?
Immunovant Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Immunovant Inc (IMVT)?
The 12-month analyst consensus target is $46.88, about 17.3% above the current $39.95. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Immunovant Inc's Altman Z-Score is 1.64, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-59.30%
Beta0.77
50D MA$36.56
200D MA$28.06
Shares out0.21B
Float0.08B
Short ratio—
Avg volume1.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—